This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Direct costs
Only direct health service costs were considered, namely drug costs, including drug wastage costs. These were taken from the Swedish pharmacopoeia. Quantities and costs were presented separately. Costs were not discounted due to the short period of analysis (less than 1 year). The price year was not stated. The authors considered all other costs relating to surgery to be equal for each procedure.
Statistical analysis of costs
A statistical analysis of costs was not performed.
Indirect Costs
Indirect costs were not considered.
Currency
Swedish kroner (Sek) Sek1.00 = US$0.12.
Sensitivity analysis
A sensitivity analysis was not performed.
Cost results
When the cost of wastage was taken into account, the mean anaesthetic drug cost was $0.58/minute for sevoflurane, $0.74/minute for propofol/alfentanil and $0.84/minute for propofol/remifentanil.
Synthesis of costs and benefits
A synthesis of costs and benefits was not applicable.
Authors' conclusions
From a cost-minimisation point of view, propofol induction, fentanyl for analgesia and maintenance with sevoflurane in oxygen nitrous oxide is the technique of choice.
